Analysis of the expression and localization of tight junction transmembrane proteins, claudin-1,-4,-7, occludin and JAM-A, in human cervical adenocarcinoma
Analysis of the expression and localization of tight junction transmembrane proteins, claudin-1,-4,-7, occludin and JAM-A, in human cervical adenocarcinoma
复制标题
DOI：
10.14670/hh-11-729
复制
发表时间：
2016-08-01
影响因子：
2
通讯作者：
Sawada, Norimasa
中科院分区：
文献类型：
--
作者：
Akimoto, Taishi;Takasawa, Akira;Sawada, Norimasa
Objective.最近报道紧密连接蛋白可用于区分肿瘤组织和非肿瘤组织。在这项研究中，我们评估了紧密连接跨膜蛋白在人宫颈腺癌和原位腺癌（AIS）中的表达和定位，并确定其表达模式是否可以区分宫颈腺癌和非肿瘤性宫颈腺体。方法.本研究纳入了55例宫颈腺癌或AIS患者。对手术标本进行封闭蛋白（CLDN）-1、-4、-7、闭合蛋白和JAM-A的化学染色。结果CLDNs和JAM-A在子宫颈AIS和腺癌中的表达水平显著高于非肿瘤性腺体。在子宫颈AIS和腺癌中，CLDN-1和JAM-A的定位扩展到整个细胞膜，而它们主要在非肿瘤性腺体中的最顶端细胞-细胞连接处表达。ROC曲线分析显示，CLDN-1和JAM-A的免疫反应成功地区分了肿瘤和非肿瘤性宫颈腺体，具有高特异性（CLDN-1，79.1%; JAM-A，79.1%）和高敏感性（CLDN-1，84.1%; JAM-A，95.5%）。结论.正如预期的那样，通过使用针对紧密连接跨膜蛋白的抗体，宫颈腺癌和非肿瘤性宫颈腺体之间存在免疫组化差异。这些结果表明，CLDN-1和JAM-A是宫颈腺癌的潜在生物标志物。
Objective. Tight junction proteins have recently been reported to be useful for distinguishing between neoplastic and non-neoplastic tissues. In this study, we evaluated the expression and localization of tight junction transmembrane proteins in human cervical adenocarcinoma and adenocarcinoma in situ (AIS), and we determined whether their expression patterns could distinguish cervical adenocarcinoma from nonneoplastic cervical glands. Methods. Fifty-five patients with cervical adenocarcinoma or AIS were included in this study. Surgical specimens were immunohistochemically stained for claudin (CLDN) -1, -4, -7, occludin, and JAM-A. Results. Significantly higher expression levels of CLDNs and JAM-A were found in cervical AIS and adenocarcinoma than in non-neoplastic glands. In cervical AIS and adenocarcinoma, localization of CLDN-1 and JAM-A was extended throughout the whole cell membranes, whereas they were predominantly expressed at the most apical cell-cell junction in non-neoplastic glands. ROC curve analysis revealed that immunoreactivities of CLDN-1 or JAM-A successfully distinguished neoplasms from nonneoplastic cervical glands with high specificity (CLDN-1, 79.1%; JAM-A, 79.1%) and high sensitivity (CLDN-1, 84.1%; JAM-A, 95.5%). Conclusions. As expected, there were immunohistochemical differences between cervical adenocarcinoma and non-neoplastic cervical glands by using antibodies against tight junction transmembrane proteins. These results suggest that CLDN-1 and JAM-A are potential biomarkers for cervical adenocarcinoma.